Adipogenesis is inhibited by brief, daily exposure to high-frequency, extremely low-magnitude mechanical signals by Rubin,  C. T. et al.
Adipogenesis is inhibited by brief, daily exposure
to high-frequency, extremely low-magnitude
mechanical signals
C. T. Rubin*†, E. Capilla‡, Y. K. Luu*, B. Busa*, H. Crawford‡, D. J. Nolan§¶, V. Mittal§¶, C. J. Rosen, J. E. Pessin‡,
and S. Judex*
Departments of *Biomedical Engineering and ‡Pharmacology and ¶Graduate Program in Genetics, Stony Brook University, Stony Brook, NY 11794;
§Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724; and The Jackson Laboratory, Bar Harbor, ME 04609
Communicated by William J. Lennarz, Stony Brook University, Stony Brook, NY, September 19, 2007 (received for review June 20, 2007)
Obesity, a global pandemic that debilitates millions of people and
burdens society with tens of billions of dollars in health care costs,
is deterred by exercise. Although it is presumed that the more
strenuous a physical challenge the more effective it will be in the
suppression of adiposity, here it is shown that 15 weeks of brief,
daily exposure to high-frequency mechanical signals, induced at a
magnitude well below that which would arise during walking,
inhibited adipogenesis by 27% in C57BL/6J mice. The mechanical
signal also reduced key risk factors in the onset of type II diabetes,
nonesterified free fatty acid and triglyceride content in the liver, by
43% and 39%, respectively. Over 9 weeks, these same signals
suppressed fat production by 22% in the C3H.B6–6T congenic
mouse strain that exhibits accelerated age-related changes in body
composition. In an effort to understand the means by which fat
production was inhibited, irradiated mice receiving bone marrow
transplants from heterozygous GFPmice revealed that 6 weeks of
these low-magnitude mechanical signals reduced the commitment
of mesenchymal stem cell differentiation into adipocytes by 19%,
indicating that formation of adipose tissue in these models was
deterred by a marked reduction in stem cell adipogenesis. Trans-
lated to the human, this may represent the basis for the nonphar-
macologic prevention of obesity and its sequelae, achieved through
developmental, rather than metabolic, pathways.
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Sixty percent of adult Americans are overweight, and obesity anddiabetes threaten close to 30% of the population (1). Annually,
these diseases consume more than $150 billion in health service
costs, yet effective pharmacologic interventions at any scale have
proven elusive (2). Even control of obesity and diabetes has proven
difficult, with a principal etiologic factor being a ‘‘sedentary life-
style’’ and a common therapeutic intervention being exercise (3).
Although the exact mechanism remains unknown, the pathways by
which exercise suppresses adipogenesis are certain to involve both
metabolic (4) and mechanical (5) factors, and a more complete
understanding will help define physical and physiologic pathways
that may, at some point, help control the pathogenesis of these
diseases (6).
It is widely accepted that exercise suppresses obesity and the
onset of type II diabetes by metabolizing calories that accumulate
through the diet (7) and regulating insulin, free fatty acids (FFA),
and triglyceride (TG) production through physiologic control of
sugar in the bloodstream (8). Thus, the inhibition of obesity and
diabetes through exercise is achieved bymetabolizing caloric intake
via increased work expenditure (9) and a proportional reduction in
hyperglycemia (10). This implies that the more strenuous and
extended the exercise, the greater the benefit in metabolizing fat
(11, 12). In some contrast to this ‘‘more is better’’ perspective, it has
recently been shown that short daily durations of high-frequency,
extremely low-level mechanical signals, three orders of magnitude
below those induced by exercise (13), can positively influence other
physiologic systems, including bone (14) and muscle (15), once
thought responsive only to intense physical challenges.
Considering that adipocytes, osteoblasts, and myocytes all derive
from a common progenitor, marrow-derived mesenchymal stem
cells (MSCs) (16), it was hypothesized that these low-magnitude
mechanical signals (LMMS), which are anabolic to the musculo-
skeletal system, would, in parallel, suppress adiposity. This would be
achieved not by metabolizing existing adipose tissue, but instead by
suppressing the differentiation of stem cells into adipocytes. Thus,
adipogenesis would be curbed via a developmental pathway, and at
a physical input well below that currently considered necessary to
suppress adiposity via exercise (17). Finally, as evidence that this
intervention could effectively influence a model genetically pre-
disposed to adiposity, the ability of these mechanical signals to
suppress fat production was examined in a congenic mouse model
that recapitulates age-related changes in body composition (18).
Results
LMMS Suppression of Adiposity in Normal B6 Mice.At baseline, body
weights of the LMMS (21.2  1.5 g) and control (CTR) (21.1 
1.7 g) mice were similar (P  0.9). Throughout the course of the
protocol, body mass of the two groups increased at similar rates
(Fig. 1). Activity patterns during the 15 min of LMMS and sham
treatment were not noticeably different from their behavior in their
cages or from each other. There were no noticeable differences in
eating behavior between groups, and weekly food intake between
LMMS (26.4 2.1 gweek1) and CTR (27.0 2.1 gweek1) mice
was essentially identical (Fig. 1). At 12 weeks, when the in vivo CT
scans were performed, the body mass of LMMS animals was not
significantly different from CTR (4.0% lower in LMMS; P  0.2)
(Table 1).
As measured at 12 weeks by in vivo CT, fat volume in the torso
of LMMS B6 mice was 27.4% lower than that measured in CTR
mice (P 0.008) (Fig. 2). Differences in body mass or food intake
failed to account for the suppressed adipose tissue measured in the
LMMSmice. Correlations between food intake and total bodymass
(r2  0.15; P  0.7) or fat volume (r2  0.008; P  0.6) were weak
and indicated that the lower adiposity in LMMS animals could not
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be explained by differences in food consumption between groups.
Whereas variations in body mass of the CTR mice correlated
strongly with fat volume (r2 0.70;P 0.0001), no such correlation
was observed in LMMS (r2 0.18; P 0.1), indicating that fat mass
contributed to weight gain in CTR but did not account for the
increase in body mass in the mechanically stimulated animals
[supporting information (SI) Fig. 5]. Body mass as a covariate
increased the P value to 0.013 whereas food intake as a covariate
did not alter the P value for the difference between CTR and
LMMS mice.
In contrast to fat volume, total lean volume of the torso (total
volume minus fat and bone) was similar between LMMS and CTR
(P  0.7) (Table 1), whereas lean volume as a ratio of body mass
was 5.0% greater in LMMS (P  0.01). Bone volume of the
skeleton, from the base of the skull to the distal region of the tibia,
as a ratio of body mass was 4.6% greater in LMMS than CTR (P
0.03). Fat volume normalized to body mass was 23.5% less in the
LMMS (P  0.004), and the ratio of fat volume to lean mass was
27.6% lower in LMMS than in CTR (P 0.005). No differences in
length of the tibia (P 0.6) or torso (P 0.6) or weight of the heart
(P  0.7) or liver (P  0.6) were identified between groups.
Fat volume data derived from in vivo CT at 12 weeks were
supported by the weights of the dissected fat pads harvested at 15
weeks, where LMMS had 26.2% less epididymal (P  0.01) and
20.8% less subcutaneous (P  0.02) fat than CTR (Table 2).
Normalized to mass, there was 22.5% less epididymal and 19.5%
less subcutaneous fat in LMMS than CTR (P  0.007).
To account for the 1.2-g body mass difference between LMMS
and CTR mice measured at 12 weeks, in vivo CT measurements of
fat volume were converted to mass equivalents. Using a density of
0.9196 gcm3 to convert fat volume to mass (19) indicated that
3.54 0.9 g of the average LMMSmousemass came from fat (13%
of total mass) whereas 4.87 1.5 g of the mass of the average CTR
mouse came from fat (17% of total mass). Thus, the lack of fat in
the LMMSanimals was, in essence, able to account for the ‘‘missing
mass’’ between the groups (P  0.01).
In parallel with the suppression of adiposity, TG in adipose tissue
of LMMS mice were 21.1% (P  0.3) lower than CTR and 39.1%
lower in the liver (P  0.02) (Fig. 3). Total nonesterified FFA
(NEFA) in adipose tissue were 37.2% less in LMMS (P  0.01),
whereas NEFA in the liver of LMMS mice was 42.6% lower (P 
0.02) than CTR. Although there was a slight decrease in fasting
glucose and insulin levels in the LMMS group (P  0.07), this was
not significantly different, suggesting that these mechanical signals
had no significant effect on liver or  cell function (Table 2).
Similarly, there was no significant change in glucose tolerance,
insulin signaling, or fatty acid oxidation in muscle, liver, or adipose
tissue (data not shown). Circulating levels of leptin were 38.3%
lower in the LMMS as compared with CTR (P  0.07), whereas
adiponectin (down 16.3%; P  0.16) and resistin (down 13%; P 
0.17) were not as markedly suppressed (Table 2).
LMMS Inhibits the Differentiation of GFP Marrow Cells into Adipo-
cytes. It has recently been reported that the adipogenic precursors
in mice are derived from bone marrow stem cells (16), an anatomic
site subject to these mechanical signals (20). Thus, GFP-labeled
recipient mice were used to determine whether LMMS suppressed
adiposity by redirecting bone marrow-derived adipogenic stem
cells. This was accomplished by examining the production of
adipocytes after GFP-labeled bone marrow transplant. When the
GFP recipients were euthanized after 6 weeks of loading (animal
age 15 weeks), the mass of LMMS was not significantly different
from CTR (3.6% lower; P  0.19). Flow cytometry demonstrated
the ratio of GFP adipocytes in the epididymal fat pad to GFP
Fig. 1. Over the course of the experimental period, no significant differences
were measured between average body mass of the B6 CTR (■) relative to
LMMS B6 mice (F). Weekly food intake over this period was also similar
between groups (n  15 in each group).
















CTR B6 28.6  2.49 5,298  1,671 17,265  1,184 183  40 18.2  1.2 606  36 232  66
LMMS B6 27.4  2.21 3,849  927 17,464  1,548 140  31 19.0  0.8 637  27 169  43
% difference 4.0 27.4 1.2 23.5 4.6 5.0 27.6
P value 0.20 0.008 0.69 0.004 0.030 0.013 0.005
Data are mean and SD, as well as percentage difference and P values, of body habitus parameters of the CTR and LMMS B6 mice at 12 weeks as defined by
in vivo microcomputed tomography (n  15 in each group; P values 0.05 are in bold).
Fig. 2. A longitudinal (Upper) and transverse (Lower, at level of dotted line)
reconstruction of subcutaneous and epididymal fat content through the torso
of a CTR (Left) and LMMS (Right) B6 mouse, performed in vivo at 12 weeks by
using CT signal parameters specifically sensitive to fat. After 12 weeks of
LMMS, the average amount of fat within the torso was 27% lower than that
of age-matched CTR.
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marrow-based MSCs to be 19% lower (P  0.018) in LMMS
relative to CTR (SI Fig. 6). These data indicating reduced com-
mitment to adipocytes were supported by the weight of the epi-
didymal fat pad after 6 weeks of LMMS, which was 12.2% less than
CTR (P  0.029).
LMMS Suppresses Age-Related Changes in Fat Composition. 6T mice
were subjected to LMMS to determine whether these mechanical
signals could suppress this animal’s predisposition to age-related
deterioration of body composition (18). At 9 weeks (16 weeks of
age), 6Tmice subject to LMMSwere 3.9% lighter (P 0.19) (Table
3), and had 21.6% less fat volume (P  0.02) (Fig. 4) than CTR.
NEFA in adipose tissue were 48.0% less in LMMS (P  0.02),
whereas TG were 25.0% lower (P  0.27). Whereas NEFA in the
liver was not influenced by LMMS (4.8% lower; P  0.69), TG
realized a 15.3% reduction by the mechanical signal (P  0.002).
Discussion
Obese children aremore prone to develop type II diabetes (21) and
increase their lifetime risk of cardiovascular disease (22). Over-
weight adults, not yet even obese, are more susceptible to chronic,
debilitating diseases and increased risk of death (23). Although
exercise remains the most readily available and generally accepted
means of curbing weight gain and the onset of type II diabetes,
compliance is poor, and the means by which these metabolic and
mechanical cues conspire to suppress adiposity and diabetes are not
fully understood. In contrast to the perception that physical signals
must be large and endured over long periods of time to offset caloric
input and control insulin production, the results presented here
indicate that the cell population(s) and physiologic process(es)
responsible for establishing fat mass and, perhaps indirectly, FFA
and TG production are readily influenced by brief exposure to
mechanical signals barely large enough to be perceived.
From a metabolic perspective, the trend toward improved glu-
cose tolerance measured here indicates that the metabolic machin-
ery of the organism has been elevated, and perhaps remains higher
even after LMMS has subsided, suggesting that a mechanosensory
element within the cell population has been triggered without the
signals being large (24). And rather than requiring an accumulation
of mechanical information over an aggregate of time to elevate
metabolic activity, perhaps these cell populations are endowedwith
a memory, or refractory period, in which their metabolic machin-
ery, once triggered, remains active even after the stimulus has
subsided (25).
Somewhat contrary to a ‘‘metabolic’’ perspective, the low inten-
sity of the daily regimen indicates that the inhibition of adipogenesis
is achieved by pathways other than an exercise-mediated increase in
metabolic activity. Indeed, the GFP recipient mice indicate that
the reduced adiposity resulting from LMMS is achieved in part by
influencing the differentiation of fat precursors, deterring MSCs
from committing to an adipocytic lineage. Even the 6T mouse
predisposed to age-related changes in body composition responded
to LMMS by suppressed adiposity. Considered in the context of
previous evidence that LMMS is anabolic to bone (26) and muscle














CTR B6 0.63  0.21 0.21  0.06 0.54  0.09 2.34  1.53 6.92  1.88 3.14  0.95
LMMS B6 0.47  0.12 0.17  0.03 0.48  0.07 1.44  0.93 5.80  2.29 2.73  0.55
% difference 26.2 20.8 10.8 38.3 16.3 13.0
P value 0.014 0.016 0.07 0.07 0.16 0.17
Data are mean and SD, as well as percentage difference andP values, of body habitus (n15 in each group) and biochemical parameters (n14 in each group)
of the CTR and LMMS B6 mice measured after euthanasia (P values 0.05 are in bold).
Fig. 3. A summary of phenotypic and biochemical differences between LMMS and CTR B6 mice indicates that LMMS reduces risk factors associated with
diabetes. Mean and SD of fat volume in the torso of CTR and LMMS B6 mice, as measured by CT scan (Upper Left), as well as by mass of the epididymal fat pad
(Lower Left). Also shown are total TG (Upper Center) and NEFA in adipose tissue (Upper Right) and TG and NEFA in liver (Lower). n  15 in each group for the
CT scans and epididymal mass, n  8 for measurements in adipose tissue, and n  12 for the liver. *, P  0.05.







tissues (15), our data suggest that LMMS may drive MSCs to
enhance themusculoskeletal system by encouraging noncommitted
stem cell precursors toward a connective tissue lineage. The com-
mon heritage of these cell systems suggest that conditions of fat gain
or bone loss could be controlled by targeting the precursors of
adipocytes and osteoblasts.
Previous studies have shown that plasma levels of leptin correlate
with the degree of adiposity, whereas the adipokines adiponectin
and resistin more closely correlate with changes in metabolic state
(27). The reduction in circulating leptin levels in theB6LMMSmice
as compared with CTR is consistent with a decrease in adipose
tissue mass, whereas the absence of a significant change in either
adiponectin or resistin levels supports a conclusion that the reduced
adiposity was achieved without altering the metabolic state of the
animals.
Among the limitations of these experiments is the range of time
periods examined, making it difficult to directly compare them
against each other (SI Fig. 7). Although each protocol was designed
to address a different question, LMMS suppressed adiposity across
all protocols, as measured by both fat mass and fat volume. Longer
protocols (e.g., 1 year) will be necessary to determine whether the
suppression of fat mass, TG, and NEFA levels persist, and shorter-
term protocols (e.g., 1 week) must be developed to identify the
molecular regulators of the response. Finally, more expansive
protocols must be used to assess whether altered adipogenesis is
correlated to changes in the quantity and quality of the musculo-
skeletal system.
There is recent in vitro evidence that high levels of mechanical
stretch can direct MSCs toward an osteoblastogenic lineage, in
preference over adipocytes (28). Here, in an in vivo system, we were
able to demonstrate that physical signals need not be large to
influence differentiation pathways and can be delivered noninva-
sively to influence the phenotype of the entire animal. Rather than
requiring high levels of mechanical distortion or damage to deter-
mine their fate, perhaps these stem cell populations are sensitive to
frequency-specific stimuli, similar to other physiologic systems
designed to monitor ‘‘exogenous signals,’’ such as vision (color),
hearing (tone), and tactile sense (pressure), and that these physical
signals are processed within specific windows of sensitivity and may
begin to shut down when the signal becomes too bright, too loud,
or too heavy. Certainly, when considered in the context of the
exceedingly small tissue strains that arise from the mechanical
signals used here, perhaps the critical component of mechanotrans-
duction should be considered the acceleration, rather than distor-
tion, as an efficient means of notifying a cell population of physical
challenges (29).
In any case, the inhibition of adipogenesis by LMMS, considered
in parallel with their anabolic potential in bone and muscle (15),
supports the presence of a systems-interdependent benefit of
exercise and the systemic consequences of a sedentary lifestyle. In
hindsight, perhaps this should not be so surprising, because bone
and muscle are well known to positively respond to mechanical
challenges, whereas fat thrives with inactivity. Arguably, these data
indicate that mesenchymal precursors perceive and respond to
mechanical ‘‘demands’’ as stimuli to differentiate down a muscu-
loskeletal pathway rather than ‘‘defaulting’’ to adipose tissues and
may, to a certain extent, etiologically interconnect age-related
increases in obesity, osteopenia, and sarcopenia.
The physiologic relevance of LMMS becomes evident upon
examination of the contractile spectra of muscle. Type IIa muscle
fibers fire in the range of 20–50 Hz (30), and, albeit small in
amplitude relative to the peak signals generated by strenuous
activities such as running, these higher-frequency signals are, over
time, a predominant component of the mechanical energy in the
musculoskeletal system (31). Conditions such as aging reduce these
higher-frequency domain signals (32) and suggest that the age-
Fig. 4. Transverse CT reconstruction performed in vivo at 9 weeks, with signal sensitivity to adipose tissue, showing fat content through the abdominal region
of the torso of a CTR (Left) and LMMS (Right) female 6T mouse. No significant difference in body mass was evident between LMMS and CTR 6T (3.9% less in LMMS),
but adipose within the torso was 22% lower in mechanically stimulated animals (P  0.02).














CTR 6T 20.43  1.27 343.6  59.2 0.19  0.04 2,005.5  656.4 0.0076  0.0014 51.51  0.77
LMMS 6T 19.63  0.93 269.2  52.5 0.10  0.04 1,503.8  474.8 0.0073  0.0011 43.6  2.67
% difference 3.9 21.6 48.0 25.02 4.82 15.3
P value 0.19 0.02 0.02 0.27 0.67 0.002
Data are mean and SD, as well as percentage difference and P values, for the CTR and LMMS 6T body habitus parameters as measured by CT at week 9 of the
protocol (n 8 in each group) and biochemical parameters in plasma (n 8 in each group) and tissues (n 4 in each group), measured directly after euthanasia
(P values 0.05 are in bold). Note that the fat volume is for a specific region of the abdomen, and not the fat volume for the entire animal.
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related bone wasting and increase in adiposity may occur not only
from diminished peak-load-bearing capacity, but the dissolution of
low-level signals caused by the sarcopenia that parallels these
conditions (33).
In parallel with the lower adiposity realized by LMMS, TG and
NEFA in adipose and liver tissue, key biochemical factors related
to type II diabetes, were suppressed in both the B6 and 6T mouse.
Numerous studies have demonstrated that dyslipidemia can have
major negative impact onmetabolism, growth, and development. In
particular, intratissue lipid accumulation (liver steatosis) and in-
tramyocellular lipids have been closely linked to insulin resistance
and are considered the best predictor for the future development
of insulin resistance (34). Although obesity results in states of
dyslipidemia, lipodystrophy (the absence of adipose tissue deposits)
can have the same negative consequence because of limited pe-
ripheral FFA and TG storage capacity (35). Thus, a physiologic
balance between lipid storage and lipid release must be maintained
for optimum metabolism. The ability to suppress adipose tissue
expansion by mechanical signals, as well as limit NEFA and TG
production, may provide a simple, nonpharmacologic approach to
limit obesity in a manner sufficient to prevent the consequences of
dyslipidemia.
LMMS were delivered to the mouse via whole-body vibration.
When considering translating this to the clinic, it is important to
note that associations persist between vibration and adverse health
conditions, including low-back pain, cartilage erosion, circulatory
disorders, and neurovestibular dysfunction (36), leading to Inter-
national Safety Organization advisories to limit human exposure to
these mechanical signals (37). At the frequency (90 Hz) and
amplitude (0.2-g peak) used in these studies, the exposure would be
considered safe for 4 h each day.
In summary, our findings indicate that brief exposure to high-
frequency LMMS markedly suppress adipogenesis and TG and
NEFA production and could lead to a unique, nonpharmacologic
intervention for the control of obesity and its sequelae, such as type
II diabetes. The fact that the signals are so low, and so brief, yet with
such striking response in the phenotype of both the growing animal
and a model of accelerated aging, suggests a means of suppressing
adipogenesis independent of a metabolic pathway. That a mechan-
ical signal anabolic to bone may simultaneously inhibit fat produc-
tion would couple the prevention of obesity to the prevention of
osteoporosis, achieved by controlling differentiation of MSCs
rather than the resident cells in adipose or skeletal tissue.
Methods
All procedures were reviewed and approved by the Stony Brook
University animal care and use committee. The overall experimen-
tal design consisted of three distinct protocols, each designed
around a different time scale to examine specific components of the
general hypothesis (SI Fig. 7). The first protocol, to determine
whether LMMS can suppress adiposity in normal male mice as
compared with CTR, began with young adult mice 7 weeks of age
and required a 15-week protocol to ensure that differences in fat
production between groups could be assayed. The second protocol,
to examine the influence of LMMS on the differentiation ofMSCs,
was shorter (6 weeks of loading), allowing an earlier evaluation of
stem cell commitment to adipocytes. Precise irradiation dosing,
dependent on animal mass, required that each mouse be at least 8
weeks of age, and considerations for animal health required that
this be followed by a week of recovery before handling. Thus, the
animals began the LMMS protocol at 9 weeks of age and were
euthanized at 15 weeks of age. The third protocol, to examine
whether LMMS could suppress adipogenesis in a congenic mouse
model prone to adiposity, began when the animals were 7 weeks old
(as in the first experiment). To facilitate comparison of body habitus
data to those reported in the literature (18), this group was
euthanized at 16 weeks of age after 9 weeks of LMMS.
Mechanical Influence on Adiposity in the Normal Mouse. Forty
C57BL/6J (B6) male mice, 7 weeks of age and given free access to
a normal chow diet, were randomly separated into two groups:
those subjected to brief periods of LMMS (n  20) or their
age-matched sham CTR (n 20). Animal weights, as well as their
individual food consumption, weremeasured weekly. For 15 weeks,
5 days per week, LMMSmice were subjected to 15 min of a 90-Hz,
0.2-g peak acceleration (1.0 g  Earth’s gravitational field, or 9.8
ms2), induced by vertical whole-body vibration via a closed-loop
feedback controlled, oscillating platform (modified from Juvent
Medical, Inc., Somerset, NJ) (38). A sinusoidal vibration at this
magnitude and frequency causes a displacement of12 m and is
barely perceptible to human touch. CTR animals were placed on an
inactive platform each day.
At 12 weeks into the protocol (19 weeks of age), in vivo
microcomputed tomography (VivaCT 40; Scanco, Bassersdorf,
Switzerland) was used to quantify fat and lean volume of the torso
(n  15 in each group) (39). The torso of each mouse was CT
scanned at an isotropic voxel size of 76 m (45 kV, 133 A, 300-ms
integration time). Torso length was defined by two anatomical
landmarks, from the distal tibia to the base of the skull. Image
segmentationwas calibrated by using the density range of a fresh fat
pad from a B6mouse unrelated to this study. Gaussian filtering was
applied ( 1.5; support 3.0) to reduce image noise before scans
were evaluated for volume.
At 15 weeks into the protocol (22 weeks of age) mice were fasted
overnight, and blood collection was performed by cardiac puncture
with the animal under anesthesia and plasma harvested by centrif-
ugation (14,000 rpm, 15 min, 4°C). Mice were euthanized by
cervical dislocation, and the different tissues (i.e., epididymal fat
pad and subcutaneous fat pads from the torso, liver, and heart) were
excised, weighed, frozen in liquid nitrogen, and stored at 80°C.
Glycerol, TG, FFA, insulin, and three adipokines (leptin, adi-
ponectin, and resistin) were measured in the plasma (n  14 per
group). TG and NEFA were measured on lipid extracts from
adipose tissue (n  8 per group) and liver (n  12 per group).
Plasma insulin levels and adipokines were measured by using
ELISA kits (Mercodia, Winston-Salem, NC; and Linco Research
andMillipore, Chicago, IL, respectively). TG and FFA/NEFA from
plasma and tissues were measured by using enzymatic colorimetric
kits (Serum Triglyceride Determination Kit from Sigma, Saint
Louis, MO; and NEFA C fromWako Chemicals, Richmond, VA).
Total lipids fromwhite adipose tissue (epididymal fat pad) and liver
were extracted and purified following the chloroform–methanol
method with some modifications (40).
GFP-Labeled Stem Cells. To determine whether LMMS influenced
the differentiation pathway of adipocyte precursors, we used a
model of bone marrow transplantation using heterozygous
C57BL/6J (B6) GFP mice as bone marrow donors. The GFP
expression in these transgenic mice is under the control of a
constitutive actin promoter; therefore, all cells within the animal
should produceGFP protein. Once implanted into a normal mouse
that does not endogenously express GFP, the fate of the bone
marrow stem cells can be monitored by the production of GFP.
Targeted as recipients, 16 wild-type male C57BL/6J (B6) mice, 8
weeks of age, were irradiated in a  cell irradiator with a Cs137
source at a total dose of 15 Gy (dose rate of 1.07 Gy/min). This
whole-body exposure had been previously determined to be lethal
to animals of this age unless they received, within 24 h, a bone
marrow transplant from a healthy donor. The following day,
irradiatedmice were injected through the tail vein with 1 107 cells
(total injection of 100 l) harvested from the bone marrow of the
GFP donor mice (41).
After 1 week of recovery, half of the GFP recipient mice (n 
8) were subjected to LMMS (as above), and half served as age-
matched sham-loaded CTR (n  8). Animals were euthanized at
6 weeks of the protocol, and the epididymal fat pad and marrow







from the tibia were harvested for examination. Adipocytes and
bone marrow cells isolated from the GFP transplanted mice were
analyzed by using the GFP fluorescence signal.
FACS analysis was performed on single-cell suspensions from
the direct isolation of the marrow and fat tissues. Adipocytes were
isolated from the epididymal fat pad bymechanical and collagenase
digestion in KRH buffer, centrifuged to remove the stromal vas-
cular compartment, and then resuspended in PBS. The cell popu-
lation in the marrow was collected by clipping both ends of the tibia
and flushing out the marrow with PBS (0.5% BSA). Red cells were
removed by incubation with lysis buffer, and the pellet of white cells
was resuspended in PBS. Samples were fixed in PBS at a final
concentration of 1.5% formalin, protected from light, and stored at
4°C for up to 1 week before analysis.
Flow cytometry data were collected by using a FACScan flow
cytometer (Becton Dickinson, San Jose, CA). For adipocyte sam-
ples, percentages were calculated based on 2,500 gated events, and
the percentage of positively stained cells was determined. For each
bone marrow sample, 10,000 gated events were collected. To help
identify MSCs within the overall cell population of the marrow, all
cells were exposed to stem cell antigen-1 (Sca-1), an antigen
previously associated with hematopoietic cells but subsequently
demonstrated to exhibit adipogenic, chondrogenic, and osteogenic
potential (42). Phycoerythrin-conjugated rat anti-mouse Sca-1 an-
tibody and isotype CTR (BDBiosciences, San Jose, CA) were used
at 1:100 dilution in PBS with 0.01% sodium azide.
Mouse Model That Recapitulates Age-Related Changes in Body Com-
position. To determine whether LMMS can influence an animal
model with a genetically driven predisposition to adiposity, 18
female C3H.B6–6T (6T) mice, 7 weeks of age, were obtained from
The Jackson Laboratory (Bar Harbor, ME). The 6T is a congenic
mouse strain derived by transferring a small genomic region of
mouse chromosome 6 from C3H/HeJ onto a C57BL/6J (B6)
background for 10 generations. The mice were initially generated
to map a major quantitative trait locus for circulating IGF1 and to
understand the physiologic and body composition changes associ-
ated with accelerated aging (18). The phenotypic characteristics of
the 16-week female 6T mouse include reduced circulating and
hepatic IGF1 and increased adiposity despite similar body weights
comparedwith the parental B6mouse (43). 6Tmice were subjected
to a 9-week loading and analysis similar to that described for the B6
long-term experiments, except that CT, performed just before
euthanasia, was spatially limited to measure only the volume of the
abdominal region.
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